“Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan”
<h4>Purpose</h4> COVID-19 infection resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to spread across the globe in early 2020. Patients with hematologic malignancies are supposed to have an increased risk of mortality from coronavirus disease of 2019 (COV...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022796/?tool=EBI |
| _version_ | 1817988826095681536 |
|---|---|
| author | Adeeba Zaki Salman Muhammad Soomar Danish Hasan Khan Hasan Shaharyar Sheikh Raheel Iftikhar Ayaz Mir Zeba Aziz Khadija Bano Hafsa Naseer Qamar un–Nisa Chaudhry Syed Waqas Imam Bokhari Munira Shabbir-Moosajee |
| author_facet | Adeeba Zaki Salman Muhammad Soomar Danish Hasan Khan Hasan Shaharyar Sheikh Raheel Iftikhar Ayaz Mir Zeba Aziz Khadija Bano Hafsa Naseer Qamar un–Nisa Chaudhry Syed Waqas Imam Bokhari Munira Shabbir-Moosajee |
| author_sort | Adeeba Zaki |
| collection | DOAJ |
| description | <h4>Purpose</h4> COVID-19 infection resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to spread across the globe in early 2020. Patients with hematologic malignancies are supposed to have an increased risk of mortality from coronavirus disease of 2019 (COVID-19) infection. From Pakistan, we report the analysis of the outcome and interaction between patient demographics and tumor subtype and COVID-19 infection and hematological malignancy. <h4>Patients and methods</h4> This multicenter, retrospective study included adult patients with a history of histologically proven hematological malignancies who were tested positive for COVID-19 via PCR presented at the oncology department of 5 tertiary care hospitals in Pakistan from February to August 2020. A patient with any known hematological malignancy who was positive for COVID-19 on RT-PCR, was included in the study. Chi-square test and Cox-regression hazard regression model was applied considering p ≤ 0.05 significant. <h4>Results</h4> A total of 107 patients with hematological malignancies were diagnosed with COVID-19, out of which 82 (76.64%) were alive, and 25 (23.36%) were dead. The significant hematological malignancy was B-cell Lymphoma in dead 4 (16.00%) and alive group 21 (25.61%), respectively. The majority of the patients in both the dead and alive group were on active treatment for hematological malignancy while they came positive for COVID-19 [21 (84.00%) & 48 (58.54%) p 0.020]. All patients in the dead group were admitted to the hospital 25 (100.00%), and among these, 14 (56.00%) were admitted in ICU with a median 11 (6–16.5) number of days. Among those who had contact exposure, the hazard of survival or death in patients with hematological malignancies and COVID-19 positive was 2.18 (CI: 1.90–4.44) times and 3.10 (CI: 2.73–4.60) times in patients with travel history compared to no exposure history (p 0.001). <h4>Conclusion</h4> Taken together, this data supports the emerging consensus that patients with hematologic malignancies experience significant morbidity and mortality resulting from COVID-19 infection. |
| first_indexed | 2024-04-14T00:38:24Z |
| format | Article |
| id | doaj.art-20f10f6ae2c84a76922308c7f9e6253f |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-14T00:38:24Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-20f10f6ae2c84a76922308c7f9e6253f2022-12-22T02:22:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01174“Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan”Adeeba ZakiSalman Muhammad SoomarDanish Hasan KhanHasan Shaharyar SheikhRaheel IftikharAyaz MirZeba AzizKhadija BanoHafsa NaseerQamar un–Nisa ChaudhrySyed Waqas Imam BokhariMunira Shabbir-Moosajee<h4>Purpose</h4> COVID-19 infection resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began to spread across the globe in early 2020. Patients with hematologic malignancies are supposed to have an increased risk of mortality from coronavirus disease of 2019 (COVID-19) infection. From Pakistan, we report the analysis of the outcome and interaction between patient demographics and tumor subtype and COVID-19 infection and hematological malignancy. <h4>Patients and methods</h4> This multicenter, retrospective study included adult patients with a history of histologically proven hematological malignancies who were tested positive for COVID-19 via PCR presented at the oncology department of 5 tertiary care hospitals in Pakistan from February to August 2020. A patient with any known hematological malignancy who was positive for COVID-19 on RT-PCR, was included in the study. Chi-square test and Cox-regression hazard regression model was applied considering p ≤ 0.05 significant. <h4>Results</h4> A total of 107 patients with hematological malignancies were diagnosed with COVID-19, out of which 82 (76.64%) were alive, and 25 (23.36%) were dead. The significant hematological malignancy was B-cell Lymphoma in dead 4 (16.00%) and alive group 21 (25.61%), respectively. The majority of the patients in both the dead and alive group were on active treatment for hematological malignancy while they came positive for COVID-19 [21 (84.00%) & 48 (58.54%) p 0.020]. All patients in the dead group were admitted to the hospital 25 (100.00%), and among these, 14 (56.00%) were admitted in ICU with a median 11 (6–16.5) number of days. Among those who had contact exposure, the hazard of survival or death in patients with hematological malignancies and COVID-19 positive was 2.18 (CI: 1.90–4.44) times and 3.10 (CI: 2.73–4.60) times in patients with travel history compared to no exposure history (p 0.001). <h4>Conclusion</h4> Taken together, this data supports the emerging consensus that patients with hematologic malignancies experience significant morbidity and mortality resulting from COVID-19 infection.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022796/?tool=EBI |
| spellingShingle | Adeeba Zaki Salman Muhammad Soomar Danish Hasan Khan Hasan Shaharyar Sheikh Raheel Iftikhar Ayaz Mir Zeba Aziz Khadija Bano Hafsa Naseer Qamar un–Nisa Chaudhry Syed Waqas Imam Bokhari Munira Shabbir-Moosajee “Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan” PLoS ONE |
| title | “Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan” |
| title_full | “Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan” |
| title_fullStr | “Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan” |
| title_full_unstemmed | “Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan” |
| title_short | “Outcomes of COVID-19 infection in patients with hematological malignancies- A multicenter analysis from Pakistan” |
| title_sort | outcomes of covid 19 infection in patients with hematological malignancies a multicenter analysis from pakistan |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022796/?tool=EBI |
| work_keys_str_mv | AT adeebazaki outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT salmanmuhammadsoomar outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT danishhasankhan outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT hasanshaharyarsheikh outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT raheeliftikhar outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT ayazmir outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT zebaaziz outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT khadijabano outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT hafsanaseer outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT qamarunnisachaudhry outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT syedwaqasimambokhari outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan AT munirashabbirmoosajee outcomesofcovid19infectioninpatientswithhematologicalmalignanciesamulticenteranalysisfrompakistan |